
Ironwood Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300PC8MR6QHH6P296 - ISIN
US46333X1081 (IRWD )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. Read full profile
Fundamentals
- Net revenue
€263.15M - Gross margin
99.7% - EBIT
€64.09M - EBIT margin
24.4% - Net income
-€5.93M - Net margin
-2.3%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Gaskins Tammi L | Chief Commercial Officer |
|
|
|
|
John Minardo | Chief Legal Officer |
|
|
|
|
Martini Gregory S. | Chief Financial Officer |
|
|
|
|
Silver Ronald | Principal Accounting Officer |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)